Johnson & Johnson Stock News

Finding dividend stocks that are reliable and have the balance sheet stability and cash flow profile to continue to grow their distributions over the long-term is what many investors are after.

Dividend kings can offer reliable income growth and capital appreciation, making them attractive for long-term investors. During our screening today, we have 22 dividend kings trading at what could be considered attractive valuations based on P/E, dividend, and analyst estimates. We take a closer look at three of these names that make the list, but all could be considered candidates to take a d...

Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to deliver 9-20% net gains by July 2026, with average risk 40% below the market. Many high-yield favorites are not 'safer' due to negative free cash flow, so investors should seek price pullbacks or fo...

This is a tricky time for investors. Most people agree that valuations have reached alarmingly high levels.

The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fireside Chat at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition ...

The Dividend Income Accelerator Portfolio delivers a 3.98% yield and 7.11% five-year dividend growth, balancing income and growth for strong risk-adjusted returns. Our portfolio is globally diversified, with reduced company and sector concentration risk, enhancing stability and lowering overall risk. Large-cap, value-focused holdings dominate, further reducing risk and supporting consistent div...

A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.